Disclosed herein are embodiments of gold nanoparticles and methods of making and using the gold nanoparticles. The disclosed gold nanoparticles have core sizes and polydispersities controlled by the methods of making the gold nanoparticles. In some embodiments, the methods of making the gold nanoparticles can concern using flow reactors and reaction conditions controlled to make gold nanoparticles having a desired core size. The gold nanoparticles disclosed herein also comprise various ligands that can be used to facilitate the use of the gold nanoparticles in a variety of applications.

Provided are a method for efficiently manufacturing a nitrogen-containing compound, which is used for manufacturing a treatment agent for integrin-related diseases, or a salt thereof and a manufacturing intermediate of the compound or a salt thereof.

A method for manufacturing a novel nitrogen-containing compound or a salt thereof includes (1) a step of obtaining a compound represented by Formula [10] or a salt thereof through an amidation reaction; and (2) a step of deprotecting the compound represented by Formula [10] or a salt thereof.

##STR00001##

The present invention relates to a novel gadolinium-based compound having a structure in which a gadolinium complex and a gallic acid are bonded to each other, a method for producing same, and an MRI contrast agent containing same.

The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., .sup.225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA. ##STR00001##

Disclosed are novel lanthanide(III) chelates including a pyridine 4-ethynylpyrazine subunit. These chelates have an excitation wavelength which allows excitation with UV LED.

Gallium-salophen compounds, and methods of using the same for the treatment of disease are disclosed.

The invention relates to complexing agents of formula (I):

##STR00001##

wherein Chrom.sub.1, Chrom.sub.2 and Chrom.sub.3 are as defined in the description. The invention also relates to lanthanide complexes obtained from these complexing agents.

The invention relates to compounds of general formula (I), ##STR00001##
in which each E independently represents O or NR.sup.1, with the proviso that at least 1 E is not O and at least 1 R.sup.1 represents a substituted C.sub.1-22 alkyl of the general formula (IIa) or (IIb) or (IIIa) or (IIIb), ##STR00002##
in which Q represents O or CH.sub.2, w represents a number from 1 to 22, q represents 1 or 2 and A.sup.+ represents a cation selected from alkali metal cations where q=1, ½ alkaline earth cations where q=2 and ammonium ions where q=1, as well as metal complexes having this ligand compound and dishwashing detergents which contain such metal complexes.

The embodiments provide a fluorescent rare earth complex having strong emission intensity and excellent durability, and also provide a security medium using the complex. The rare earth complex according to the embodiment comprises a rare earth ion, a diphosphine dioxide ligand and a β-diketone ligand wherein two phosphorus atoms contained in the diphosphine dioxide ligand individually have substituents different from each other.